The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension

Blood Pressure

Volumn 5, Issue 5, 1996, Pages 285-291

  Nalbantgil, Istemi ^a,b   Önder, Remzi ^a   Killiçcioglu, Bülent ^a   Boydak, Bahar ^a   Terzioglu, Ender ^a   Yilmaz, Hasan ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Felodipine ER; Hypertension; Left ventricular hypertrophy; Patients

Indexed keywords

FELODIPINE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029764643     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059609078061     Document Type: Article

References (38)

1. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988; 35 (Suppl 5): 1-4.
2. Levy D, Andersen KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy. Am J Cardiol 1987; 60(7): 560-5.
3. McLenahan J, Henderson E, Morris K, Dargie H. Ventricular arrhythmias in left ventricular hypertrophy. New Engl J Med 1987; 317: 787-2.
4. Messerli FH. Considerations in treating hypertension focus on risk factors. J Hum Hypertens 1990; 4 (Suppl 5): 3-6.
5. Messerli FH, Ventura HO, Elizardi DI, Dunn FG, Frohlich ED. Hypertension and sudden death increased ventricular hypertrophy activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22.
6. Devereux RB, Koren MJ, De Simone G, Okin PM, Kliegfield P. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993; 14 (Suppl D): 8-15.
7. Hansson L. Reversal of cardiac and vascular hypertrophy by antihypertensive therapy. Am Heart J 1991; 121: 995-1000.
8. Yurenev AP, Dyakonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G, et al. Am J Hypertens 1992; 5: 182S-9S.
9. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Int Med 1991; 114: 345-52.
10. Motz WH, Vogt M, Scheler S, Strauer BE. Pharmacotherapeutic effects of antihypertensive agents on myocardium and coronary arteries in hypertension. Eur Heart J 1992; 13 (Suppl D): 100-6.
11. Dahllöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metanalysis of 109 treatmant studies. Am J Hypertens 1992; 5: 95-110.
12. Nalbantgil I, Önder R, Kilhçcioglu B, Atabay G. Regression on left ventricular hypertrophy with different calcium antagonists in cases with hypertension. Cardiovasc Drugs Ther 1991; 5 (Suppl 3): 350A.
13. Schmieder RE, Messerli FH, Garavaglio GE, Nunes BD. Cardiovascular effects of Verapamil in essential hypertension. Circulation 1987; 76: 1143-55.
14. Grandi AM, Venco A, Barzizza F, Casadei B, Marchesi E. Finardi G. Effect of enalapril on left ventricular mass and performance in essential hypertension. Am J Cardiol 1989; 63: 1093-7.
15. Gosse P, Grellet J, Bononon S, Tanosse L, Besse P, Dallocchio M. Effects of Perindopril on left ventricular hypertrophy, coronary blood flow and mechanical properties of cardiac muscle in renovascular hypertensive rats. Am J Hypertens. 1991; 4 (Suppl 1): 235-9.
16. Dunn FG, Venturo HO, Messerli FH, Kobrin I, Frohlich ED. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation 1987; 76: 254-8.
17. Wollam GL, Hall WD, Porter VD, Douglas MB, Unger DJ, Blumenstein BA, et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983; 75 (Suppl 3A): 100-10.
18. Tsopons J, Leenen FH. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension 1988; 11: 376-80.
19. Leenen FH, Smith DL, Farkas RM, Reeves RA, Marques Julio A. Vasodilators and regression of left ventricular hypertrophy. Am J Med 1987; 82: 969-78.
20. Edgar B, Lundborg P, Regårdh CG. Clinical pharmacokinetics of Felodipine. Drugs 1987; 34 (Suppl 3): 16-27.
21. Ljung B. Vascular selectivity of Felodipine. Drugs 1985; 29 (Suppl 2): 46-58.
22. Mace PJE, Stallard TJ, Littlen WA. Felodipine in hypertension. Eur J Clin Pharmacol 1985; 29: 383-9.
23. Sluiter HE. Felodipine in Hypertensive patients. Drugs 1987; 34 (Suppl 3): 97-106.
24. Hansson BG, Lyngstam G, Lyngstam O. Antihypertensive effect of Felodipine combined with beta blockade. Drugs 1985; 29 (Suppl 2): 131-6.
25. Santoro G, Savonitti S, Di Bello V, Alberti D, Giusti C. Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. Am J Cardiol 1991; 68: 457-62.
26. Ekelund LG, Ulvenstam G, Walldius G, Åberg A. Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. Am J Cardiol 1994; 73: 658-60.
27. Cerasola G, Cottone S, Nardi E, Fulantelli MA, Carone MB, Dignoto G. Reversal of cardiac hypertrophy and left ventricular function with the calcium antagonist felodipine in hypertensive patients. J Hum Hypertens 1990; 4: 703-8.
28. Wetzchewald D, Klaus D, Garanin G, Lohr E, Hoffman J. Regression of left ventricular hypertrophy during longterm antihypertensive treatment - a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med 1992; 231: 303-8.
29. Leenen FHH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639-45.
30. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613-8.
31. Messerli FH. Effect of antihypertensive therapy on left ventricular hypertrophy and on its pathophysologic sequele. Blood Pressure 1992; 1 (Suppl): 35-7.
32. Koren MH, Ulin RJ, Laragh JH, Devereux RD. Reduction in left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens 1991; 4: A1-2.
33. Koren MJ, Devereux RD, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991:114: 345-52.
34. Messerli FH, Soria F Selection of antihypertensive therapy, cardiac and extracardiac considerations. Review. Cardiology 1992; 81 (4-5): 316-24.
35. Liebson PR, Granditis GA, Dianzumba S, Prineas RJ, Grimm RH Jr. Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995; 91 (3): 698-706.
36. Epstein M. Renal effects of calcium antagonists with focus on felodipine. Cardiovasc Drug Rev 1994; 12 (4): 344-56.
37. Lederle RM, Wetzchewald. Lederle E. Antihypertensive efficacy and trough to peak ratios of felodipine ER 5 and 10 mg in patients with primary hypertension. A double blind, cross-over study using ambulatory blood pressure measurement. Drug Invest 1994; 8 (6): 369-76.
38. Devereaux RB, Pickering TG, Harshfield GA, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly occurring stress. Circulation 1983; 68: 470-6.